C4 Therapeutics, Inc.
General ticker "CCCC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $160.3M (TTM average)
C4 Therapeutics, Inc. follows the US Stock Market performance with the rate: 45.9%.
Estimated limits based on current volatility of 6.1%: low 4.03$, high 4.55$
Factors to consider:
- Total employees count: 110 (-24.1%) as of 2024
- Top business risk factors: Profitability and sustainability, Operational and conduct risks, Labor/talent shortage/retention, Litigation risks, Economic downturns and volatility
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.44$, 3.96$]
- 2026-12-31 to 2027-12-31 estimated range: [1.59$, 4.21$]
Financial Metrics affecting the CCCC estimates:
- Positive: with PPE of -1.5 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 71.46 > 64.29
- Positive: -14.17 < Investing cash flow per share per price, % of -5.11
Short-term CCCC quotes
Long-term CCCC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $20.76MM | $35.58MM | $35.95MM |
| Operating Expenses | $159.79MM | $155.20MM | $151.17MM |
| Operating Income | $-139.03MM | $-119.61MM | $-115.22MM |
| Non-Operating Income | $7.82MM | $14.43MM | $10.35MM |
| Interest Expense | $1.37MM | $0.00MM | $0.00MM |
| R&D Expense | $117.71MM | $110.64MM | $104.24MM |
| Income(Loss) | $-131.21MM | $-105.19MM | $-104.87MM |
| Taxes | $1.28MM | $0.13MM | $0.12MM |
| Net Income(Loss)* | $-132.49MM | $-105.32MM | $-104.99MM |
| Stockholders Equity | $246.11MM | $215.99MM | $256.59MM |
| Assets | $376.45MM | $349.60MM | $359.07MM |
| Operating Cash Flow | $-106.84MM | $-65.16MM | $-98.69MM |
| Capital expenditure | $1.71MM | $0.18MM | $0.61MM |
| Investing Cash Flow | $158.35MM | $-51.27MM | $-8.60MM |
| Financing Cash Flow | $45.49MM | $45.34MM | $126.40MM |
| Earnings Per Share** | $-2.67 | $-1.52 | $-1.27 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.